This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seifert, K.
Right arrow Articles by Croft, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seifert, K.
Right arrow Articles by Croft, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 73-79, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.73-79.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

Karin Seifert and Simon L. Croft*

Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

Received 9 August 2005/ Returned for modification 5 September 2005/ Accepted 13 October 2005

The interaction of miltefosine with amphotericin B, sodium stibogluconate, paromomycin, and sitamaquine was assessed in vitro and additionally for the first three combinations in vivo. In vitro interactions were indifferent for miltefosine combined with amphotericin B (mean sums of fractional inhibitory concentrations [mean {sum}FICs] ranging from 1.22 to 1.51 at the 50% effective concentration [EC50] level and 1.08 to 1.38 at the EC90 level), sitamaquine (mean {sum}FICs from 1.33 to 1.38 and 1.0 to 1.02, respectively), and paromomycin (mean {sum}FICs from 0.79 to 0.93 at the EC50 and 0.77 to 1.35 at the EC90 level). Some synergy was observed for miltefosine combined with sodium stibogluconate (mean {sum}FICs from 0.61 to 0.75 at EC50 and 0.49 to 0.97 at EC90). Different interactions were found in vivo, where the highest potentiation of miltefosine activity was achieved with amphotericin B (activity enhancement index [AEI] of up to 11.3). No significant interaction was observed when miltefosine was combined with sodium stibogluconate (AEI of up to 2.38). The potentiation of miltefosine in vivo was also achieved with the combination of miltefosine and paromomycin (AEI of up to 7.22).

* Corresponding author. Present address: Drugs for Neglected Diseases Initiative, 1 Place Saint Gervais, 1201 Geneva, Switzerland. Phone: 41 (0)22 906 9238. Fax: 41 (0)22 906 9231. E-mail: scroft{at}dndi.org.

Antimicrobial Agents and Chemotherapy, January 2006, p. 73-79, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.73-79.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Seifert, K., Escobar, P., Croft, S. L. (2010). In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65: 508-511 [Abstract] [Full Text]  
  • Aguiar, M. G., Silva, D. L., Nunan, F. A., Nunan, E. A., Fernandes, A. P., Ferreira, L. A. M. (2009). Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. J Antimicrob Chemother 64: 1234-1240 [Abstract] [Full Text]  
  • Serrano-Martin, X., Payares, G., De Lucca, M., Martinez, J. C., Mendoza-Leon, A., Benaim, G. (2009). Amiodarone and Miltefosine Act Synergistically against Leishmania mexicana and Can Induce Parasitological Cure in a Murine Model of Cutaneous Leishmaniasis. Antimicrob. Agents Chemother. 53: 5108-5113 [Abstract] [Full Text]  
  • Singh, N., Gupta, R., Jaiswal, A. K., Sundar, S., Dube, A. (2009). Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother 64: 370-374 [Abstract] [Full Text]  
  • Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J. (2008). The Relationship between Leishmaniasis and AIDS: the Second 10 Years. Clin. Microbiol. Rev. 21: 334-359 [Abstract] [Full Text]  
  • Menez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P. M., Barratt, G. (2006). Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. Antimicrob. Agents Chemother. 50: 3793-3800 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»